(Note: “This is an initial public offering of our Class A ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00. Unlike certain other special purpose acquisition company initial public offerings (“SPAC IPOs”), investors in this offering will not receive warrants that would become exercisable following completion of our initial business combination.”)

Our sponsor is an affiliate of Cormorant Asset Management, LP (“Cormorant”), a leading life sciences focused investment firm with over $2 billion in assets under management as of June 30, 2020. Our Chairman and Chief Executive Officer Bihua Chen founded Cormorant, and our Chief Financial Officer Jay Scollins is the Chief Financial Officer and Chief Operating Officer of Cormorant. Since its inception in 2013, Cormorant has focused exclusively on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant primarily focuses on financing rounds taking place prior to initial public offerings known as “crossovers.” Cormorant is among the most active life-science crossover investors in terms of number of investments since 2015 with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Principia Biopharma Inc., Turning Point Therapeutics Inc., Myokardia Inc., BridgeBio Pharma Inc., Forma Therapeutics Holdings Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion.